Article contents
Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness
Published online by Cambridge University Press: 14 May 2021
Abstract
We evaluated adverse drug events (ADEs) by chart review in a random national sample of 428 veterans with coronavirus disease 2019 (COVID-19) who received tocilizumab (n = 173 of 428). ADEs (median time, 5 days) occurred in 51 of 173 (29%) and included hepatoxicity (n = 29) and infection (n = 13). Concomitant medication discontinuation occurred in 22% of ADE patients; mortality was 39%.
- Type
- Concise Communication
- Information
- Copyright
- © The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
References
- 1
- Cited by